Prenumeration
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company is scaling up the production capacity, focusing on higher margin extracts, and developing new proprietary ingredients targeting eye disorders, which constitute strong value drivers ahead. Having a broad product portfolio with a market demand, Eevia is estimated to enter a rapid growth phase where an EBIT of EUR 4.8m is forecasted. Based on an applied EV/EBIT multiple of 4.5x on the estimated EBIT of EUR 4.8m in year 2026, and a discount rate of 12%, this yields an implied value per share of SEK 4.9 (3.8) in a Base scenario. Given that Eevia takes steps in the right direction and is able to capitalise on the structural market trends, Analyst Group see a potential for the Company to reduce the valuation discount going forward.
Read the equity research report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis related to Eevia Health Plc. Readers may assume that Analyst Group has received compensation for making the analysis. The client has not had any opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.